| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The specific molecular targets of Picroside III are not fully characterized. As an iridoid glycoside from Picrorhiza scrophulariiflora, it is known for various biological activities including hepatoprotective, anti-inflammatory, and intestinal protective effects. The compound has been studied for its potential to repair intestinal mucosal damage and reduce intestinal inflammation in mice. Iridoid glycosides from Picrorhiza species are known to interact with multiple cellular targets involved in inflammation and oxidative stress pathways. However, the precise molecular targets of Picroside III remain to be fully elucidated through systematic target identification studies.
|
|---|---|
| ln Vitro |
In vitro studies on Picroside III are limited. The compound has been detected and quantified in leaf-derived calli of Picrorhiza kurroa, an endangered medicinal plant species. Based on the known activities of related iridoid glycosides, Picroside III may exhibit anti-inflammatory, antioxidant, and hepatoprotective activities in cell-based assays. The compound has been studied for its potential to repair intestinal mucosal damage and reduce inflammation. However, specific in vitro activity data for Picroside III, including IC50 values or detailed cellular mechanism studies, are not widely available in the published literature.
|
| ln Vivo |
In vivo studies have demonstrated that Picroside III has the potential to repair intestinal mucosal damage and reduce intestinal inflammation in mice. This finding suggests that the compound has therapeutic potential for inflammatory bowel diseases and other gastrointestinal disorders. As a component of Picrorhiza kurroa, which has been used in traditional medicine for various treatments, Picroside III is believed to contribute to the pharmacological effects of the crude herb. However, detailed in vivo efficacy data, including dose-response relationships and mechanistic studies, are limited.
|
| Enzyme Assay |
The in vitro receptor binding and enzyme assays for Picroside III are not well-documented in the available literature. As an iridoid glycoside, the compound's interactions with potential molecular targets could be studied using standard biochemical techniques. These might include radioligand binding assays for receptor targets, enzyme activity assays for enzymatic targets, and cell-based reporter assays for signaling pathway modulation. However, specific protocols for studying Picroside III have not been published. For researchers interested in studying this compound, protocols would need to be developed based on the known activities of related iridoid glycosides from Picrorhiza species.
|
| Cell Assay |
Cellular assays for Picroside III are not well-documented in the available literature. For similar iridoid glycosides, typical cellular assays involve culturing relevant cell lines such as intestinal epithelial cells, hepatocytes, or immune cells and treating them with varying concentrations of the compound. Cells are then assessed for markers of inflammation, oxidative stress, or cell viability using techniques such as ELISA, Western blotting, or quantitative PCR. However, specific protocols for Picroside III have not been published.
|
| Animal Protocol |
In vivo animal studies for Picroside III have been conducted in mouse models of intestinal inflammation. The compound is typically administered orally or intraperitoneally at various doses, and its effects on intestinal mucosal integrity and inflammation are assessed. Intestinal tissue samples are collected for histopathological analysis and measurement of inflammatory markers. The compound's ability to repair intestinal mucosal damage and reduce inflammation has been demonstrated in these models. Further studies are needed to fully characterize the in vivo pharmacological profile of Picroside III.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Picroside III are not available in the current literature. As an iridoid glycoside with a molecular weight of 538.50, the compound would be expected to have moderate oral bioavailability and undergo metabolic transformation. The compound is typically stored as powder at -20degC for up to 3 years or at 4degC for up to 2 years. Solubility information is limited, but related iridoid glycosides are typically soluble in organic solvents such as DMSO, ethanol, and methanol. Detailed pharmacokinetic parameters such as half-life, clearance, and bioavailability have not been determined for this compound.
|
| Toxicity/Toxicokinetics |
Toxicological data for Picroside III are not available in the published literature. As a natural product from Picrorhiza scrophulariiflora, which has a long history of traditional medicinal use, the compound is presumed to have a reasonable safety profile. Picrorhiza species have been consumed as a traditional medicine with no major safety concerns reported. However, the specific toxicity profile of purified Picroside III has not been systematically evaluated in preclinical studies. Standard toxicological assessments would be needed to establish the safety profile of this compound for any potential therapeutic applications.
|
| References | |
| Additional Infomation |
Picroside III is a research-grade natural product isolated from Picrorhiza scrophulariiflora (Hu Huang Lian), a traditional Chinese medicinal herb. It is an iridoid glycoside with a molecular formula of C25H30O13 and a molecular weight of 538.50. The compound has demonstrated potential to repair intestinal mucosal damage and reduce intestinal inflammation in mice. Picrorhiza species have been used traditionally for the treatment of liver disorders, respiratory conditions, and inflammation. Picroside III is one of several bioactive iridoid glycosides found in these plants. The compound is not approved for clinical use and is available only for research purposes.
|
| Molecular Formula |
C25H30O13
|
|---|---|
| Molecular Weight |
538.4979
|
| Exact Mass |
538.168
|
| CAS # |
64461-95-6
|
| PubChem CID |
23986034
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
791.2±60.0 °C at 760 mmHg
|
| Flash Point |
266.9±26.4 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.678
|
| LogP |
-2.58
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
38
|
| Complexity |
912
|
| Defined Atom Stereocenter Count |
11
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~92.85 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.32 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (2.32 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8570 mL | 9.2851 mL | 18.5701 mL | |
| 5 mM | 0.3714 mL | 1.8570 mL | 3.7140 mL | |
| 10 mM | 0.1857 mL | 0.9285 mL | 1.8570 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
